Company intelligence / Profile preview

Xeno Biosciences

Cambridge, Massachusetts, United Statesxenobiosciences.com ↗

Ownership: Private
Employees: ~4
Development stage: Phase 1

Overview

Xeno Biosciences developed XEN‑101, an oral small molecule designed to induce weight loss by shifting the gut microbiome to a state similar to that seen after gastric bypass surgery. The drug showed high tolerability and safety in early clinical trials but did not demonstrate sufficient efficacy for weight loss. In early 2025, LPOXY Therapeutics acquired key assets from Xeno, including clinical data and IP, to repurpose the compound as SIDIPREV™ for prevention of C. difficile infection in hospitalized patients.[6]

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small molecules (oral, gut-restricted compounds)[1][3][5]
Industry: Biotech

Drug pipeline

1 asset

XEN-101

Discontinued

Beyond the preview

Go deeper on Xeno Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xeno Biosciences.

Explore the full profile